Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 70)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Prednisone |
Approved, Vet_approved |
Phase 4 |
|
53-03-2 |
5865 |
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
2 |
|
Hydrocortisone succinate |
Approved |
Phase 4 |
|
2203-97-6 |
3643 |
Synonyms:
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
Cortisol 21-(hydrogen succinate)
Cortisol succinate
HYDROCORTISONE HEMISUCCINATE
|
Hydrocortisone hemisuccinate anhydrous
Hydrocortisone hydrogen succinate
HYDROCORTISONE SUCCINATE
Hydroxycortisone succinate
NSC-7576
|
|
3 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
Phase 4 |
|
50-03-3 |
|
Synonyms:
21-O-acetylcortisol
BARQUINOL HC
CHLOROMYCETIN HYDROCORT
COLIFOAM
CORTEF ACETATE
CORTIFOAM
Cortisol 21-acetate
CORTRIL
CORTUCID
DRICORT
EPIFOAM
FRAMYCORT
FUCIDIN H
GENTICIN HC
GENTISONE HC
|
GPPE EAR SUSP
GPPE EYE CRM
GPPE FOAM AERO
HC45 HYDROCORT
HEMSOL-HC
HEPACORT PLUS
HYDROCAL
HYDROCORTISONE 21-ACETATE
HYDROCORTISONE ACETATE
HYDROCORTONE
LANACORT
MICORT-HC
NEO-CORTEF
NSC-741
ORABASE HCA
|
|
4 |
|
Hydrocortisone |
Approved, Vet_approved |
Phase 4 |
|
50-23-7 |
3640 5754 |
Synonyms:
(11ALPHA,14BETA)-11,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11Β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(1S,2R,10S,11S,14S,15S,17S)-14,17-DIHYDROXY-14-(2-HYDROXYACETYL)-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11Β,17α,21-trihydroxy-4-pregnene-3,20-dione
11Β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
ACETASOL HC
ACTICO МИХАИЛRT
Acticort
Acticort®|Efmody®|Plenadren®
Aeroseb HC
Aeroseb-HC
Alacort
Ala-cort
Ala-scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort-HC
ANUGESIC HC
Anusol HC
ANUSOL PLUS HC
ANUSOL SOOTHING RELIEF
Anusol-HC
Aquacort
Aquanil HC
Balneol-HC
Barseb HC
Basan-corti
Beta-HC
b-HC
CaldeCORT spray
CALMURID HC
CANESTEN HC
Cetacort
Chronocort
CIPRO HC
Clear aid
Cleiton
Cobadex
Colocort
Compound F
CORLAN
Cor-oticin
Cortanal
Cor-tar-quin
Cort-dome
Cortef
CORTENEM
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisolonum
Cortisporin
Cortisporin otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
CORTRIL
Cremesone
Cremicort-H
Cutisol
DAKTACORT
DAKTACORT HYDROCORT
Delacort
DERMA CARE HYDROCORT
Dermacort
Derm-aid
DERMASPRAY DEMANG
Dermil
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
ECONACORT
Ef corlin
Efcorbin
Efcortelan
EFCORTELAN P
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EURAX-HC
EURAX-HYDROCORT
Evacort
EXE-CORT
Ficortril
Fiocortril
Flexicort
Foille insetti
Genacort
GERMOLOIDS HC
Glycort
GREGODERM
gyno-Cortisone
HC
|
HC #1
HC #4
HC (HYDROCORTISONE)
HC45
H-Cort
Heb cort
Heb-cort
Hi-cor
Hidalone
hidro-Colisona
Hidrocortisona
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
hydro-Colisona
Hydrocort
HYDROCORT IN CALAMINE OILY
HYDROCORT IN CETOMACROGOL FOR A
HYDROCORT IN WTE SOFT PARAF
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
Hydrocortisone sodium phosphate
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisonum
Hydrocortistab
Hydrocortisyl
HYDROCORTONE
HYDRODERM
HYDRODERM HC
hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone lotion
Idrocortisone
Incortin-H
Incortin-hydrogen
JUNGLE FOR
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
Locoid
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
MILDISON LIPOCREAM
Milliderm
neo-Cort-dome
neo-Cortef
Neosporin-H ear
Nogenic HC
NSC-10483
Nutracort
NYBADEX
Nystaform-HC
Ophthocort
Optef
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
OTOSEPTIL
Otosone-F
OTOSPORIN
Pediotic suspension
Penecort
PERINAL
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Prepcort
Prestwick_265
Prevex HC
Proctocort
PROCTOCREAM HC
Proctofoam
PROCTOFOAM HC
PROCTOSEDYL
Protocort
QUINOCORT
Racet
Rectoid
Reichstein's substance m
Remederm HC
Sanatison
Scalpicin capilar
Schericur
Scheroson F
SENTIAL HC
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Tarcortin
Terra-cortril
TERRA-CORTRIL NYSTATIN
Texacort
Timocort
TIMODINE
Topicort
TOPISONE
Transderma H
Traumaide
TRI-CICATRIN
U-cort
Uniderm
UNIROID
UNIROID HC
Vioform-hydrocortisone
VoSol HC
Vytone
XYLOPROCT
Zenoxone
β-HC
|
|
5 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
6 |
|
Hormones |
|
Phase 4 |
|
|
|
7 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
8 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
9 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
10 |
|
Anesthetics |
|
Phase 4 |
|
|
|
11 |
|
Hydrocortisone 17-butyrate 21-propionate |
|
Phase 4 |
|
|
|
12 |
|
Diazoxide |
Approved |
Phase 3 |
|
364-98-7 |
3019 |
Synonyms:
Diazossido
DIAZOXIDE
Diazoxido
Diazoxidum
Eudemine
EUDIMINE
Hyperstat
|
MUTABASE
NSC-64198
NSC-76130
Proglycem
Proglycem®|SCH-6783|SRG-95213
SCH-6783
SRG-95213
|
|
13 |
|
Exenatide |
Approved, Investigational |
Phase 3 |
|
141758-74-9 |
45588096 |
Synonyms:
AC 2993
AC002993
AC-002993
AC2993
AC-2993
AC2993A
AC-2993A
AC-2993LAR
BYDUREON
BYDUREON BCISE
BYDUREON PEN
|
BYETTA
DA-3091
Exenatida
EXENATIDE
EXENATIDE SYNTHETIC
Exendin 4
EXENDIN-4
ITCA-650
LY2148568
LY-2148568
SYNTHETIC EXENDIN-4
|
|
14 |
|
Glucagon |
Approved |
Phase 3 |
|
16941-32-5 |
16133228 16186314 |
Synonyms:
[<sup>125</sup>I]-glucagon
GCG(53-81)
GLUCAGEN HYPOKIT
GLUCAGON
Glucagon (recombinant dna origin)
GLUCAGON EMERGENCY KIT
|
GLUCAGON RECOMBINANT
Glucagon, human
Glucagon, porcine
GLUCAGONE
GLUCAGONUM
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
|
|
15 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
16 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
17 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
18 |
|
Glucagon-Like Peptide 1 |
|
Phase 3 |
|
|
|
19 |
|
Incretins |
|
Phase 3 |
|
|
|
20 |
|
Anti-Obesity Agents |
|
Phase 3 |
|
|
|
21 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
22 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
23 |
|
Oxytocin |
Approved, Vet_approved |
Phase 2 |
|
50-56-6 |
439302 53477758 |
Synonyms:
(2S)-2-[({1-[(4R,7S,10S,13S,16S,19R)-19-amino-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl}(hydroxy)methylidene)amino]-N-[(C-hydroxycarbonimidoyl)methyl]-4-methylpentanimidate
(Arg8)-vasopressin
(Arg8)-vasotocin
[<sup>3</sup>H]oxytocin
alpha-Hypophamine
Argipressin
Argpressin acetate
Biotinyl-(arg8)-vasopressin
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
Disulfide bridge cys1-cys6
Gly-leu-pro-c
Ocytocin
|
ORASTHIN
Oxitocina
OXT
OXYTOCIN
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
PITOCIN
SID29217903
SID50111741
SYNTOCINON
SYNTOMETRINE
SYT670
TTA-121
|
|
24 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
25 |
|
Trametinib |
Approved |
Phase 2 |
|
871700-17-3 |
11707110 |
Synonyms:
GSK 1120212
GSK1120212
GSK-1120212
GSK1120212|GSK1120212B|GSK212|JTP 74057|Mekinist®|trametinib dimethyl sulfoxide
GSK1120212B
GSK212
JTP 74057
|
JTP-74057
MEKINIST
TMT212
TRAMETINIB
TRAMÉTINIB
TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIBUM
|
|
26 |
|
Dabrafenib |
Approved, Investigational |
Phase 2 |
|
1195765-45-7 |
44462760 |
Synonyms:
DABRAFENIB
DRB436
GSK2118436
GSK-2118436
|
GSK2118436|GSK2118436A|Tafinlar®
GSK2118436a
GSK-2118436A
TAFINLAR
|
|
27 |
|
Vemurafenib |
Approved |
Phase 2 |
|
918504-65-1 |
42611257 |
Synonyms:
BRAF(V600E) KINASE INHIBITOR RO5185426
N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-1-PROPANESULFONAMIDE
PLX 4032
PLX4032
PLX-4032
PLX4032|RG7204|Zelboraf®
RG7204
|
RG-7204
RO-5185426
RO-51-85426
VEMURAFENIB
Vémurafénib
Vemurafenibum
Zelboraf
|
|
28 |
|
Memantine |
Approved, Investigational |
Phase 2 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
29 |
|
Dopamine |
Approved |
Phase 2 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
30 |
|
Peginterferon alfa-2b |
Approved |
Phase 2 |
|
215647-85-1, 99210-65-8 |
|
Synonyms:
Interferon alfa-2b
Intron A
Peginterferon alfa-2b
PEGINTRON
|
PEG-INTRON
PegIntron®|Sylatron®
rIFN-alpha-2b
Unitron PEG
|
|
31 |
|
Racemethionine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
59-51-8, 63-68-3, 348-67-4 |
6137 |
Synonyms:
(+-)-Methionine
(+/-)-2-amino-4-(methylmercapto)butyric acid
(2S)-2-Amino-4-(methylsulfanyl)butanoate
(2S)-2-Amino-4-(methylsulfanyl)butanoic acid
(2S)-2-Amino-4-(methylsulphanyl)butanoate
(2S)-2-Amino-4-(methylsulphanyl)butanoic acid
(2S,3R)-2-AMMONIO-3-HYDROXYBUTANOATE
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(L)-Methionine
(S)-(+)-Methionine
(S)-2-Amino-4-(methylthio)butanoate
(S)-2-Amino-4-(methylthio)-butanoate
(S)-2-Amino-4-(methylthio)butanoic acid
(S)-2-Amino-4-(methylthio)-butanoic acid
(S)-2-Amino-4-(methylthio)butyrate
(S)-2-Amino-4-(methylthio)butyric acid
(S)-Methionine
2-amino-4-(methylmercapto)Butyric acid
2-Amino-4-(methylsulfanyl)butanoate
2-Amino-4-(methylsulfanyl)butanoic acid
2-Amino-4-(methylsulphanyl)butanoate
2-Amino-4-(methylsulphanyl)butanoic acid
2-Amino-4-(methylthio)butanoate
2-Amino-4-(methylthio)butanoic acid
2-Amino-4-(methylthio)butyrate
2-amino-4-(methylthio)-Butyric acid
2-Amino-4-(methylthio)butyric acid
2-Amino-4-methylthiobutanoate
2-amino-4-Methylthiobutanoic acid
a-Amino-g-methylmercaptobutyrate
a-Amino-g-methylmercaptobutyric acid
Acimethin
alpha-Amino-alpha-aminobutyric acid
alpha-amino-gamma-(methylthio)Butyric acid
alpha-Amino-gamma-methylmercaptobutyrate
alpha-Amino-gamma-methylmercaptobutyric acid
Bo-xan
Cymethion
DL-2-amino-4-(methylthio)Butanoic acid
DL-2-amino-4-(methylthio)Butyric acid
DL-2-amino-4-(methylthio)-Butyric acid
DL-2-amino-4-Methylthiobutanoic acid
DL-Methionine
DL-Methioninum
e 161b
FEMA 3301
gamma-Methylthio-alpha-aminobutyrate
gamma-Methylthio-alpha-aminobutyric acid
g-Methylthio-a-aminobutyrate
g-Methylthio-a-aminobutyric acid
Hmet
|
H-Met-H
H-Met-OH
L(-)-Amino-alpha-amino-alpha-aminobutyric acid
L(-)-Amino-gamma-methylthiobutyric acid
L-(-)-Methionine
L-(−)-METHIONINE
L-2-Amino-4-(methylthio)butyric acid
L-2-Amino-4methylthiobutyrate
L-2-Amino-4methylthiobutyric acid
L-2-Amino-4-methylthiobutyric acid
L-a-Amino-g-methylmercaptobutyrate
L-a-Amino-g-methylmercaptobutyric acid
L-a-Amino-g-methylthiobutyrate
L-a-Amino-g-methylthiobutyric acid
L-alpha-Amino-gamma-methylmercaptobutyrate
L-alpha-Amino-gamma-methylmercaptobutyric acid
L-alpha-Amino-gamma-methylthiobutyrate
L-alpha-Amino-gamma-methylthiobutyric acid
L-gamma-Methylthio-alpha-aminobutyric acid
Liquimeth
L-Isomer methionine
L-MET
L-Methionin
L-Methionine
L-Methionine Z
L-Methioninum
L-Α-amino-γ-methylmercaptobutyrate
L-Α-amino-γ-methylmercaptobutyric acid
M
Mepron
Met
Methilanin
Methionin
Methionine
Methionine, L isomer
Methionine, L-isomer
Methioninum
Metionina
Neo-methidin
NSC-22946
Padameth
Pedameth
Poly-L-methionine
Polymethionine
Racemethionine
Racemethionine, usan
S-Methionine
S-Methyl-L-homocysteine
Toxin war
Xanthophyll
Α-amino-γ-methylmercaptobutyrate
Α-amino-γ-methylmercaptobutyric acid
|
|
32 |
|
Insulin, Globin Zinc |
|
Phase 2 |
|
|
|
33 |
|
Insulin |
|
Phase 2 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
34 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
35 |
|
CKD732 |
|
Phase 2 |
|
|
|
36 |
|
topoisomerase I inhibitors |
|
Phase 2 |
|
|
|
37 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
38 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
39 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
40 |
|
Fluorodeoxyglucose F18 |
|
Phase 2 |
|
|
|
41 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
42 |
|
Dopamine Agents |
|
Phase 2 |
|
|
|
43 |
|
Antiparkinson Agents |
|
Phase 2 |
|
|
|
44 |
|
Excitatory Amino Acid Antagonists |
|
Phase 2 |
|
|
|
45 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
46 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
47 |
|
Vorinostat |
Approved, Investigational |
Phase 1 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
48 |
|
Bortezomib |
Approved, Investigational |
Phase 1 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
49 |
|
Lenograstim |
Approved, Investigational |
Phase 1 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
50 |
|
Temozolomide |
Approved, Investigational |
Phase 1 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
Interventional clinical trials:
(show all 50)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions |
Unknown status |
NCT02190994 |
Phase 4 |
Hydrocortisone;Prednisone |
2 |
Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial |
Unknown status |
NCT00517959 |
Phase 3 |
|
3 |
Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy |
Completed |
NCT02860923 |
Phase 3 |
Exenatide;Placebo |
4 |
Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions |
Completed |
NCT00306683 |
Phase 3 |
DIAZOXIDE |
5 |
Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study |
Completed |
NCT00892073 |
Phase 2 |
Diazoxide;Metformin |
6 |
Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy |
Completed |
NCT02842723 |
Phase 2 |
|
7 |
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension |
Completed |
NCT02063295 |
Phase 2 |
ZGN-440 sterile diluent;ZGN-440 for injectable suspension |
8 |
Phase II Trial of Irinotecan in Children With Refractory Solid Tumors |
Completed |
NCT00004078 |
Phase 2 |
irinotecan hydrochloride |
9 |
Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity |
Completed |
NCT01484873 |
Phase 2 |
Exenatide |
10 |
Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome |
Completed |
NCT02849743 |
Phase 2 |
Syntocinon;Placebo (for Syntocinon) |
11 |
Nivolumab and DAY101 for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults |
Recruiting |
NCT05465174 |
Phase 2 |
Nivolumab;DAY101 |
12 |
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection |
Recruiting |
NCT02792582 |
Phase 2 |
|
13 |
Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma |
Recruiting |
NCT05525273 |
Phase 2 |
Oral dabrafenib and trametinib |
14 |
Methionine PET/CT Studies In Patients With Cancer |
Recruiting |
NCT00840047 |
Phase 2 |
Methionine |
15 |
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas |
Recruiting |
NCT03224767 |
Phase 2 |
Vemurafenib;Cobimetinib |
16 |
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection |
Active, not recruiting |
NCT01419067 |
Phase 2 |
^1^8F-fluorodeoxyglucose;^1^1C-methionine |
17 |
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study |
Active, not recruiting |
NCT03194906 |
Phase 2 |
Memantine |
18 |
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma |
Not yet recruiting |
NCT05233397 |
Phase 2 |
Tocilizumab |
19 |
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma |
Not yet recruiting |
NCT05286788 |
Phase 2 |
Binimetinib Oral Tablet [Mektovi] |
20 |
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma |
Terminated |
NCT01964300 |
Phase 2 |
|
21 |
Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms |
Completed |
NCT00019578 |
Phase 1 |
|
22 |
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas |
Completed |
NCT00994500 |
Phase 1 |
vorinostat;bortezomib |
23 |
Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors |
Completed |
NCT00052780 |
Phase 1 |
O6-benzylguanine;temozolomide |
24 |
A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors |
Completed |
NCT00100880 |
Phase 1 |
lenalidomide |
25 |
Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors |
Completed |
NCT00063973 |
Phase 1 |
cilengitide |
26 |
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors |
Completed |
NCT01076530 |
Phase 1 |
vorinostat;temozolomide |
27 |
A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS |
Completed |
NCT00363272 |
Phase 1 |
ispinesib |
28 |
A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
Completed |
NCT00946335 |
Phase 1 |
veliparib;temozolomide |
29 |
A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS |
Completed |
NCT00053963 |
Phase 1 |
romidepsin |
30 |
Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study |
Completed |
NCT01119599 |
Phase 1 |
Gamma-Secretase Inhibitor RO4929097;Temozolomide |
31 |
Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors |
Terminated |
NCT00110032 |
Phase 1 |
EF5 |
32 |
A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA |
Terminated |
NCT01088763 |
Phase 1 |
gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone |
33 |
Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma |
Unknown status |
NCT00949156 |
|
|
34 |
Examining Sleep and Family Functioning in Pediatric Craniopharyngioma Using Ecological Momentary Assessment |
Completed |
NCT03330080 |
|
|
35 |
Weight Gain in Surgically Treated Adult-onset Craniopharyngioma |
Completed |
NCT01968603 |
|
|
36 |
Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage |
Completed |
NCT04937335 |
|
|
37 |
Prospective, Multi-Center Survey Study of Children and Adolescents With Craniopharyngioma |
Completed |
NCT00258453 |
|
|
38 |
Social Participation After Childhood Craniopharyngioma |
Completed |
NCT03139526 |
|
|
39 |
Intraoperative Use of a MR Tomography System Combined With Neuronavigation - Analysis of the Craniopharyngioma Subgroup ("Intraoperative Nutzung Eines Kernspintomographie-Systems in Direkter Kopplung Mit Einem Neuronavigations-System") |
Completed |
NCT01206543 |
|
|
40 |
KRANIOPHARYNGEOM 2007 - Multicenter Prospective Study of Children and Adolescents With Craniopharyngioma |
Completed |
NCT01272622 |
|
|
41 |
Cross Sectional Study of Sleep-wake and Melatonin Patterns in Patients Treated for Craniopharyngiomas Compared to Matched Controls |
Completed |
NCT01881854 |
|
|
42 |
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens |
Completed |
NCT00919750 |
|
|
43 |
KRANIOPHARYNGEOM Registry 2019 Multicenter Registry for Patients With Childhood-onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts |
Recruiting |
NCT04158284 |
|
|
44 |
A Phase 0/Feasibility Trial of Tocilizumab in Children and Adolescents With Newly- Diagnosed or Recurrent/Progressive Adamantinomatous Craniopharyngioma |
Recruiting |
NCT03970226 |
Early Phase 1 |
Tocilizumab |
45 |
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology |
Recruiting |
NCT04648462 |
|
|
46 |
A Prospective Longitudinal Quality of Life Study in Patients Undergoing Endoscopic Endonasal Skull Base Surgery |
Recruiting |
NCT04087902 |
|
|
47 |
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers |
Active, not recruiting |
NCT02162732 |
|
|
48 |
Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy |
Enrolling by invitation |
NCT03610906 |
|
|
49 |
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
Withdrawn |
NCT02194452 |
|
|
50 |
Deep Brain Stimulation for Hypothalamic Obesity: A Surgical & Neuroimaging Study |
Withdrawn |
NCT03708913 |
|
|
|